Applied Evidence

Refining your approach to hypothyroidism treatment

Author and Disclosure Information

 

References

Elderly patients are at higher risk for adverse effects of thyroid over-replacement, including atrial fibrillation and osteoporosis. While there have been no randomized trials examining target TSH levels in this population, a reasonable recommendation is a goal TSH level of 4 to 6 mIU/L for elderly patients ≥ 70 years.4

CASE

As a result of the patient’s elevated TSH level and symptoms of hypothyroidism, you start levothyroxine 150 mcg/d by mouth, counsel her on potential adverse effects, and schedule a follow-up visit with another TSH check in 6 weeks.

Follow-up laboratory studies 6 weeks later reveal a TSH level of 5.86 mIU/L (reference range, 0.45-4.5 mIU/L) and a free T4 level of 0.74 ng/dL (reference range, 0.8-2.8 ng/dL). Based on those results, you increase the dose of levothyroxine to 175 mcg/d.

Advancing age (> 70 years) and extreme obesity (BMI > 40) are independent risk factors for decreased levothyroxine absorption.

At her follow-up visit 12 weeks after initial presentation, her TSH level is 3.85 mIU/L. She reports feeling better overall with less fatigue, and she has lost 5 pounds since her last visit. You recommend she continue levothyroxine 175 mcg/d after reviewing medication compliance with the patient and ensuring she is indeed taking it in the morning, at least 30 minutes prior to eating. With improved but not resolved symptoms, she agrees to follow-up with repeat TSH laboratory studies in 6 weeks to determine whether further dose adjustments are necessary. Given that she is of reproductive age and her TSH level is suboptimal for pregnancy, you caution her about heightened pregnancy/fetal risks with a suboptimal TSH and recommend that she use reliable contraception.

CORRESPONDENCE
Christopher Bunt, MD, FAAFP, 5 Charleston Center Drive, Suite 263, MSC 192,Charleston, SC 29425; buntc@musc.edu

Pages

Recommended Reading

FDA panel supports Vascepa expanded indication for CVD reduction
Journal of Clinical Outcomes Management
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
Journal of Clinical Outcomes Management
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
Journal of Clinical Outcomes Management
Nearly one in five U.S. adolescents have prediabetes
Journal of Clinical Outcomes Management
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
Journal of Clinical Outcomes Management
Vitamin D alone does not reduce fracture risk
Journal of Clinical Outcomes Management
Improving Nephropathy Screening in Appalachian Patients With Diabetes Using Practice-Wide Outreach
Journal of Clinical Outcomes Management
Noninjectable modes of insulin delivery coming of age
Journal of Clinical Outcomes Management
Thyroid dysfunction is common in patients with diabetes
Journal of Clinical Outcomes Management
Endocrine Society advises on use of romosozumab for osteoporosis
Journal of Clinical Outcomes Management